1-11 of 11
Tamir Shragai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment Journey of Octogenarian Patients Outside Clinical Trials

Dor Shpitzer, Yael C. Cohen, Tamir Shragai, Guy Melamed, Anat Reiner-Benaim, Irit Avivi Mazza
Journal: Blood
Blood (2024) 144 (Supplement 1): 3777.
https://doi.org/10.1182/blood-2024-205689
Published: 2024
Journal Articles

Treatment Modalities and Outcomes of Multiple Myeloma Patients with Spinal Cord Compression: A Single Center Experience

Tamir Shragai, Yael Illouz, Natan Melamed, Svetlana Trestman, Moshe Mittelman, Inna Zetserov, Irit Mazza Avivi, Yael C. Cohen
Journal: Blood
Blood (2024) 144 (Supplement 1): 6932.
https://doi.org/10.1182/blood-2024-207068
Published: 2024
Journal Articles

Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma

Yael C. Cohen, Mor Zada, Shuang-Yin Wang, Assaf Weiner, Natan Melamed, Polina Stepensky, Moshe E Gatt, Shlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, Irit Avivi Mazza, Anna Gurevich Shapiro, Iuliana Vaxman, Tamir Shragai, Paulina Chalan, Eyal David, Ido Amit
Journal: Blood
Blood (2023) 142 (Supplement 1): 341.
https://doi.org/10.1182/blood-2023-190178
Published: 2023
Journal Articles

Smoldering Multiple Myeloma Progressing to Active Multiple Myeloma Vs De-Novo Active Multiple Myeloma - a Comparison of Disease Characteristics, Organ Involvement and Outcomes in a Real-Life Multicenter Retrospective Cohort Study

Yael C. Cohen, Gil Fridberg, Inbar Cohen, Renana Robinson, Iuliana Vaxman, Tamir Shragai, Svetlana Trestman, Tomer Ziv-Baran, Natan Melamed, Pia Raanani, Irit Avivi Mazza
Journal: Blood
Blood (2023) 142 (Supplement 1): 4728.
https://doi.org/10.1182/blood-2023-186140
Published: 2023
Journal Articles

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

Eyal Lebel, Vladimir Vainstein, Paolo Milani, Giovanni Palladini, Tamir Shragai, Noa Lavi, Hila Magen, Assayag Miri, Irit Avivi Mazza, Moshe E Gatt
Journal: Blood
Blood (2023) 142 (Supplement 1): 6763.
https://doi.org/10.1182/blood-2023-173317
Published: 2023
Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Yael C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Inna Tzoran, Vladimir Vainstein, Noa Lowenton-Spier, Natan Melamed, Ella Krayzler, Ilana Pereg, Irit Avivi Mazza
Journal: Blood
Blood (2023) 142 (Supplement 1): 2014.
https://doi.org/10.1182/blood-2023-185830
Published: 2023
Journal Articles

Outcomes of Acute Myeloid Leukemia Patients Suffering from an Additional Active Malignancy Treated with Venetoclax and Azacitidine: A Single Center Experience

Yakir Moshe, Shai Levi, Miriam Neaman, Roi Gat, Mor Levi, Nili Eilati, Gil Fridberg, Yotam Bornstein, Tamir Shragai, Tsipora Neuman, Roy Vitkon, Eliya Shachar, David Sarid, Ofer Merimsky, Moshe Mittelman, Irit Avivi Mazza
Journal: Blood
Blood (2023) 142 (Supplement 1): 5929.
https://doi.org/10.1182/blood-2023-186234
Published: 2023
Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Yael C Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Noa Lowenton-Spier, Liron Gez-Aaronson, Natan Melamed, Irit Avivi
Journal: Blood
Blood (2022) 140 (Supplement 1): 10131–10132.
https://doi.org/10.1182/blood-2022-164722
Published: 2022
Journal Articles

Single Cell RNA Sequencing in Patients Enrolled in a Selinexor Clinical Trial Reveals Overexpression of Alternative Nuclear Export Pathways Associated with Resistance to Selinexor in Refractory Multiple Myeloma

Yael C Cohen, Mor Zada, Shuang-Yin Wang, Ohad S. Bentur, Evgeni Chubar, Amos Cohen, Noa Lavi, Hila Magen, Moshe Gatt, Miri Zektser, Merav Leiba, Galia Stemer, Tamir Shragai, Irit Avivi, Assaf Weiner, Ido Amit
Journal: Blood
Blood (2021) 138 (Supplement 1): 2725.
https://doi.org/10.1182/blood-2021-149701
Published: 2021
Journal Articles

Multiple Myeloma Oligosecretory Relapse, a Non-Negligible Phenomenon. Frequency, Clinical Characteristics and Outcomes in a Single Center

Itai Zamir, Tamir Shragai, Svetlana Trestman, Tomer Ziv Baran, Efrat Luttwak, Shai Levy, Irit Avivi, Yael C Cohen
Journal: Blood
Blood (2021) 138 (Supplement 1): 3772.
https://doi.org/10.1182/blood-2021-151255
Published: 2021
Journal Articles

Characteristics and Outcome of Multiple Myeloma Patients Presenting with Anemia Only: a Retrospective Multi-Center Study

Tamir Shragai, MD, Moshe E. Gatt, MD, Adir Shaulov, MD, Eirini Katodritou, MD, Theodora Triantafyllou, MD, Noa Lavi, MD, Anastasia Pouli, MD PhD, Anastasia Sioni, Iuliana Vaxman, MD BA, Miri Zektser, MD, Chezi Ganzel, MD, Noam Benyamini, MD, Svetlana Trestman, MD, Tomer ziv Baran, PhD, Yael C Cohen, MD, Irit Avivi, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5578.
https://doi.org/10.1182/blood-2018-99-116372
Published: 2018